Lung cancer is the most common cause of superior vena cava syndrome (SVCS) and requires timely recognition and management. The syndrome is rarely an oncologic emergency in the absence of tracheal compression and airway compromise. Treatment depends on the etiology of the obstructive process. Treatment should also be individualized and should not be undertaken until a diagnosis is obtained. Most patients with SVCS secondary to lung cancer can be treated with appropriately directed chemotherapy or radiotherapy. With the refinement of endovascular stents, percutaneous stenting of the SVC is being increasingly used as primary treatment modality. Thrombotic occlusion can be treated with appropriate lytic agents. In rare circumstances, surgical decompression can be performed; bypass or replacement of the SVC results in immediate improvement in the majority of cases and can be accomplished with low morbidity.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
References and Recommended Reading
Hunter W: History of aneurysm of the aorta with some remarks on aneurysms in general. Medical Observations and Inquiries (London) 1757, 1:323.
Stokes W: A Treatise on the Diagnosis and Treatment of Diseases of the Chest. Dublin: Hodges and Smith; 1837:370.
Rosenblatt MB: Lung cancer in the 19th century. Bull Hist Med 1964, 38:395.
Mcintyre FT, Sykes EM: Obstruction of the superior vena cava: a review of the literature and report of two personal cases. Ann Interny Med 1949:925.
Markman M: Diagnosis and management of superior vena cava syndrome. Cleve Clin J Med 1999, 66:59.
Fincher RE: Superior vena cava syndrome: experience in a teaching hospital. South Med J 1987, 80:1243.
Parish JM, Marschke RF, Dines DE, et al.: Etiologic considerations in superior vena cava syndrome. Mayo Clin Proc 1981, 56:407.
Banker VP, Maddison FE: Superior vena cava syndrome secondary to aortic disease: report of two cases and review of the literature. Dis Chest 1967, 51:656.
Kamiya K, Nahata Y, Naiki K, et al.: Superior vena cava syndrome. Vasc Dis 1967, 4:59.
Ahmann FR: A reassessment of the clinical implications of the superior vena cava syndrome. J Clin Oncol 1984, 2:961.
Lockridge SK, Knibbe WP, Doty DB: Obstruction of the superior vena cava. Surgery 1979, 85:14.
Chen JC, Bongard F, Klein SR: A contemporary perspective on superior vena cava syndrome. Am J Surg 1990, 160:207–211.
Inoue H, Shohtse A, Koide S, et al.: Resection of the superior vena cava for primary lung cancer: 5 years’ survival. Ann Thorac Surg 1990, 50:661–662.
Dartevelle PG, Chapelier AR, Pastorino U, et al.:Long-term follow-up after prosthetic replacement of the superior vena cava combined with resections of mediastinal-pulmonary malignant tumors. J Thorac Cardiovasc Surg 1991, 102:29–65.
Perez CA, Presant CA, VanAmburg AL: Management of superior vena cava syndrome. Semin Oncol 1978, 5:123.
Salsali M, Clifton EE: Superior vena caval obstruction with carcinoma of the lung. Surg Gynecol Obstet 1965, 121:783.
Escalante CP: Causes and management of superior vena cava syndrome. Oncology 1993, 7:61.
Nogeire C, Mincer F, Botstein C: Long survival in patients with bronchogenic carcinoma complicated by superior vena cava obstruction. Chest 1979, 75:325.
Nesbitt JC: Surgical management of superior vena cava syndrome. In Lung Cancer: Principles and Practice. Philadelphia: Lippincott Williams & Wilkins; 1996:671–681.
Yellin A, Rosen A, Reichert N, et al.: Superior vena cava syndrome: the myth—the facts. Am Rev Respir Dis 1990, 141:1114.
Perez CA, Simpson JR,: Role of irradiation in the management of superior vena cava syndrome. Int J Radiat Oncol Biol Phys 1987, 3:531.
Netter FH: Superior vena cava syndrome. The CIBA Collection of Medical Illustrations: Respiratory System. West Caldwell, NJ: CIBA Pharmaceutical Company; 1980:164.
Baker GL, Barnes JH: Superior vena cava syndrome: etiology, diagnosis, and treatment. Am J Crit Care 1992, 1:54.
Adelstein DJ: Managing three common oncologic emergencies. Cleve Clin J Med 1991, 586:457.
Helms SR, Carlson MD: Cardiovascular emergencies. Semin Oncol 1989, 16:463.
Stanford W, Doty DB: The role of venography and surgery in the management of patients with superior vena cava obstruction. Ann Thorac Surg 1986, 41:158.
Hussey JJ, Katz S, Yayer WM: The superior vena cava syndrome: report of thirty-five cases. Am Heart J 1946, 31:1.
Gooding GA, Hightower DR, Moore EH, et al.: Obstruction of the superior vena cava or subclavian veins: sonographic diagnosis. Radiology 1986, 159:663–665.
Mancuso L, Pitrolo F, Bondi F, et al.: Echocardiographic recognition of mediastinal masses. Chest 1988, 93:144–148.
Sharma RP, Keller CE, Shetty PC, et al.: Superior vena cava obstruction: evaluation with digital subtraction angiography. Radiology 1986, 160:845.
Abner A: Approach to the patient who presents with superior vena cava obstruction. Chest 1993, 103:394s-397s.
Schraufnagel DE, Hill R, Leech JA, et al.: Superior vena cava obstruction. Am J Med 1981, 70:1169.
Davenport D, Ferree C, Blake D, et al.: Response of superior vena cava syndrome to radiation therapy. Cancer 1976, 38:1577.
Kirschner PA: Mediastinoscopy in superior vena cava obstruction. In Mediastinoscopy: Proceedings of an International Symposium. Edited by Jepssen O, Ruhbek-Soreneon H. Odense, Denmark: Odense University Press; 1971:40.
Callejas MA, Rami R, Catalan M, et al.: Mediastinoscopy as an emergency diagnostic procedure in superior vena cava syndrome. Scand J Thorac Cardiovasc Surg 1991, 25:137.
Little AG, Golomb HM, Ferguson MK, et al.: Malignant superior vena cava obstruction reconsidered: the role of diagnostic surgical intervention. Ann Thorac Surg 1985, 40:285.
Jahangiri M, Taggart DP, Goldstraw P: Role of media-stinoscopy in superior vena cava obstruction. Cancer 1993, 71:3006.
Sculier JP, Evans WK, Feld R, et al.: Superior vena caval obstruction syndrome in small cell lung cancer. Cancer 1986, 57:847–851.
Greenlee RT, Murray T, Bolden S, Wingo PA: Cancer statistics. CA Cancer J Clin 2000, 50:7.
Choi NC, Doucette JA: Improved survival of patients with unresectable non-small-cell bronchogenic carcinoma by an innovated high-dose en-bloc radiotherapeutic approach. Cancer 1981, 48:101.
Parker S, Tong T, Bolden S, et al.: Cancer statistics. CA Cancer J Clin 1996, 65:5–27.
Sherry S: Clinical management of the thrombosed vessel: an overview. Angiology 1982, 33:6–10.
Marder VJ, Bele WR: Fibrinolytic Therapy. Philadelphia: JB Lippincott; 1987:1393–1437.
Sculier JP, Feld R: Superior vena cava obstruction syndrome: recommendations for management. Cancer Treat Rev 1985, 12:209–218.
Smith NL, Ravo B, Soroff HS, Khan SA: Successful fibrinolytic therapy for superior vena cava thrombosis secondary to long-tern total parenteral nutrition. J Parenteral Enteral Nutr 1985, 9:55–57.
Matthews JA, Blake HA, Hall DJ: Iatrogenic superior vena cava syndrome treated with streptokinase. Gynecol Oncol 1987, 26:119–122.
Meister FL, McLaughlin TF, Tenney RD, Sholkoff SD:Urokinase: a cost-effective alternative treatment of superior vena cava thrombosis and obstruction. Arch Intern Med 1989, 149:1209–1210.
Gray B, Olin JW, Graor RA, Young JR, et al.: Safety and efficacy of thrombolytic therapy for superior vena cava syndrome. J Am Coll Cardiol 1990, 15:193A.
Ruckley CV, Boulton FE, Redhead D: The treatment of venous thrombosis of the upper and lower limbs with ‘APSAC’ (p-anisoylated streptokinase-plasminogen complex). Eur J Vasc Surg 1987, 1:107–112.
Greenberg S, Kosinski R, Daniels J: Treatment of superior vena cava thrombosis with recombinant tissue type plasminogen activator. Chest 1991, 99:1298–1301.
Goldhaber SZ, Kessler CM, Heit J, et al.: Randomized controlled trial of tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet 1988, 2:293–298.
Magnani B, for the PAIMS Investigators: Plasminogen Activator Italian Multicenter Study (PAIMS). Comparison of intravenous recombinant single-chain human tissue-type plasminogen activator (rt-PA) with intra-venous streptokinase in acute myocardial infarction. J Am Coll Cardiol 1989, 13:19–26.
Collen D, Stassen JM, Verstraete M: Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis: effect of molecular form and dose of activator, age of thrombosis, and route of administration. J Clin Invest 1983, 71:368–376.
Fraschini G, Jadeja J, Lawson M, et al.: Infusion of urokinase for the lysis of thrombosis associated with permanent central venous catheters in cancer patients. J Clin Oncol 1987, 5:672–678.
Armstrong BA, Perez CA, Simpson JR, Hederman MA:Role of irradiation in the management of superior vena cava syndrome. Int J Radiat Oncol 1987, 13:531–539.
Rodrigues CI, Njo KH, Karim AB: Hypofractionated radiation therapy in the treatment of superior vena cava syndrome. Lung Cancer 1993, 10:221–228.
Rosch J, Bedell JE, Putnam J, et al.: Gianturco expand-able wire stents in the treatment of superior vena cava syndrome recurring after maximum-tolerance radiation. Cancer 1987, 60:1243–1246.
Charnsangavej C, Carrasco CH, Wallace S, et al.:Stenosis of the vena cava: preliminary assessment of treatment with expandable metallic stents. Radiology 1986, 161:295–298.
Rocchini AP, Meliones JN, Beckman RH, et al.: Use of balloon-expandable stents to treat experimental peripheral pulmonary artery and superior vena caval stenosis: preliminary experience. Pediatr Cardiol 1992, 13:92–96.
Wright KC, Wallace S, Charnsangavej C, et al.:Percutaneous endovascular stents: an experimental evaluation. Radiology 1985, 156:69–72.
Mullins CE, O’Laughlin MP, Vick GW, et al.: Implanta-tion of balloon-expandable intravascular grafts by catheterization in pulmonary arteries and systemic veins. Circulation 1988, 77:188–199.
Sherry CS: Successful treatment of SVC syndrome by venous angioplasty. Am J Roentgenol 1986, 147:834–835.
Hochrein J, Bashore TM, O’Laughlin MP, Harrison JK:Percutaneous stenting of superior vena cava syndrome: a case report and review of the literature. Am J Med 1998, 104:78–84. A case presentation of a patient with complete occlusion of the SVC who underwent successful vena caval revascularization with placement of balloon expandable metallic stents. It also provides a review of published reports on the use of stents for SVCS, demonstrating that stents can be used with excellent results.
Furui S, Sawada S, Kuramoto K, et al.: Gianturco stent placement in malignant caval obstruction: analysis of factors for predicting the outcome. Radiology 1995, 195:147–152.
Crowe MTI, Davies CH, Gaines PA: Percutaneous management of superior vena cava occlusions. Cardiovasc Intervent Rad 1995, 18:367–372.
Dondelinger RF, Goffette P, Kurdziel J, Roche A: Expandable metal stents for stenosis of the venae cavae and large veins. Semin Intervent Radiol 1991, 8:252–263.
Watkinson AF, Hansell DM: Expandable Wallstent for the treatment of obstruction of the superior vena cava. Thorax 1993, 48:915–920.
Dyet JF, Nicholson AA, Cook AM: The use of the Wallstent endovascular prosthesis in the treatment of malignant obstruction of the superior vena cava. Clin Radiol 1993, 48:381–385.
Rosemblum J, Leef J, Messersmith R, et al.: Intravascular stents in the management of acute superior vena cava obstruction of benign etiology. J Parenteral Enteral Nutr 1994, 18:362–366.
Antonucci F, Salomonowitz E, Stuckman G, et al.:Placement of venous stents: clinical experience with a self-expanding prosthesis. Radiology 1992, 183:394–397.
Zollikofer CL, Antonucci F, Stuckman G, et al.: Use of the Wallstent in the venous system including hemodialysis-related stenoses. Cardiovasc Intervent Radiol 1992, 15:334–341.
Solomon N, Wholey MH, Jarmolowski CR: Intravascular stents in the management of superior vena cava syndrome. Cathet Cardiovasc Diagn 1991, 23:245–252.
Elson JD, Becker GJ, Wholey MH, Ehrman KO: Vena caval and central venous stenoses: management with Palmaz balloon-expandable intraluminal stents. J Vasc Interv Radiol 1991, 2:215–223.
Palmaz JC: Balloon-expandable intravascular stent. AJR 1988, 150:1263–1269.
Rosch J, Uchida BT, Hall LD, et al.: Gianturco-Rosch expandable Z-stents in the treatment of superior vena cava syndrome. Cardiovasc Interv Radiol 1992, 15:319–327.
Oudkerk M, Heystraten FMJ, Stoter G: Stenting in malignant vena caval obstruction. Cancer 1993, 71:142–146.
Swada S, Fujiwara Y, Koyama T, et al.: Application of expandable metallic stents to the venous system. Acta Radiol 1992, 33:156–159.
Irving JD, Dondelinger RF, Reidy JF, et al.: Gianturco self-expanding stents: clinical experience in the vena cava and large veins. Cardiovasc Interv Radiol 1992, 15:328–333.
Kishi K, Sonomura T, Mitsuzane K, et al.: Self-expand-able metallic stent therapy for superior vena cava syndrome: clinical observations. Radiology 1993, 189:531–535.
Nicholson A: Treatment of malignant superior vena cava obstruction: metal stents or radiation therapy. J Vasc Interv Radiol 1997, 8:781–788. A prospective study looking at the results of treating malignant superior vena cava obstruction by means of percutaneous self-expanding stent insertion or by means of radiation therapy. This study suggests that percutaneous stent insertion in malignant superior vena cava obstruction fulfills the requirements of a palliative procedure better than radiation therapy.
Edwards RD, Jackson JE: Case report: superior vena caval obstruction treated by thrombolysis, mechanical thrombectomy, and metallic stents. Clin Radiol 1993, 48:215–217.
Effler DB, Groves LK: Superior vena cava obstruction. J Thorac Cardiovasc Surg 1962, 43:574.
Ahmann FR: A reassessment of the clinical implications of the superior vena cava syndrome. J Clin Oncol 1984, 2:961–969.
Doty DB: Bypass of superior vena cava: six years experience with spiral vein graft for obstruction of the superior vena cava due to benign and malignant disease. J Thorac Cardiovasc Surg 1982, 83:326.
Doty DB, Baker WH: Bypass of the superior vena cava with spiral vein graft. Ann Thorac Surg 1976, 22:490.
Doty DB, Doty JR, Jones KW: Bypass of superior vena cava. Fifteen years’ experience with spiral vein graft for obstruction of superior vena cava caused by benign disease. J Thorac Cardiovasc Surg 1990, 99:889.
Masuda H, Ogata T, Kikuchi K, et al.: Longevity of expanded polytetrafluoroethylene grafts for superior vena cava. Ann Thorac Surg 1989, 48:376.
Moghissi K, Dhumale R, Sench M: Innominate bypass graft for malignant superior vena caval obstruction. Paper presented to the Society of Thoracic and Cardio-vascular Surgeons of Great Britain and Ireland; London:1983.
Dartevelle PG, Chapelier AR, Pastorino U, et al.:Long-term follow-up after prosthetic replacement of the superior vena cava combined with resection of mediastinal-pulmonary malignant tumors. J Thorac Cardiovasc Surg 1991, 102:259.
Nakahara K, Ohno K, Mastumura A, et al.: Extended operation for lung cancer invading the aortic arch and superior vena cava. J Thorac Cardiovasc Surg 1989, 97:428.
Lai WW, Wu MH, Chou NS, Lin MY: Surgery for malignant involvement of the superior vena cava. J Formos Med Assoc 1992, 91:991.
Larsson S, Lepore V: Technical options in reconstruction of large mediastinal veins. Surgery 1992, 111:311.
Adelstein DJ, Hines JD, Carter SG, et al.: Thromboembolic events in patients with malignant superior vena cava syndrome and the role of anticoagulation. Cancer 1988, 62:2258–2262.
About this article
Cite this article
Wudel, L.J., Nesbitt, J.C. Superior vena cava syndrome. Curr. Treat. Options in Oncol. 2, 77–91 (2001). https://doi.org/10.1007/s11864-001-0019-3
- Stent Placement
- Superior Vena
- Superior Vena Cava
- Main Drug Interaction